Latest prOfile sets stage fOr spectacular advances
| From Name: |
Caroline Fitch |
| From Address: |
fvqpqot@helloasia.com |
| Date Received: |
02/24/2005 - 1:00:01 am |
| Spam Score: |
5.4 |
| Category: |
Investment |
View Spam Assassin Report :: Add/View Comments |
Email Preview:
Martin Nutraceuticals Commences Expansion in G|oba|
Nutraceutical Marketplace. Watch MTNU on Thursday! Martin
Nutraceuticals Inc. (MTNU) Approximate Float: 2.5 Mil|ion 30-Day
Target: 2.00 [...]
|
Email Message:
Return-Path:
Received: from The.Server.IP.Address ([222.99.155.117])
by admin.domain.com (8.12.3/8.12.3/Debian-7.1) with SMTP id j1O6iepl000800
for ; Thu, 24 Feb 2005 00:44:41 -0600
Received: from schoolgirlish.echinatex.com ([81.171.8.137])
by littleneck.echinatex.com (Sun Java System Messaging Server 6.1 HotFix 0.01 (built
Aug 25 2004)) with ESMTP id for
Recipient@domain.com; Thu, 24 Feb 2005 00:42:41 -0600 (IST)
Received: from chorale.linkeasy.net ([198.182.207.3])
by schoolgirlish.echinatex.com
(Sun Java System Messaging Server 6.1 HotFix 0.00 (built Aug 29 2004))
with ESMTP id for Recipient@domain.com
(ORCPT Recipient@domain.com); Thu, 24 Feb 2005 05:44:41 -0100 (IST)
Date: Thu, 24 Feb 2005 10:36:41 +0400
From: "Caroline Fitch"
To:
Subject: Latest prOfile sets stage fOr spectacular advances
Message-ID:
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7Bit
Martin Nutraceuticals Commences Expansion in G|oba| Nutraceutical
Marketplace.
Watch MTNU on Thursday!
Martin Nutraceuticals Inc. (MTNU)
Approximate Float: 2.5 Mil|ion
30-Day Target: 2.00
Emerging Company Poised for Great Gr0wth in the Nutraceutical Industry!
MTNU is becoming quickly recognized in the nutraceutica| marketp|ace
which wi|l surpass 74.4 bi||ion in the year 2007. With a growing
demand
for nutraceutical products that provide not only hea|th benefits, but
also prevent and provide treatment for disease, MTNU provides high
quality products that use proprietary and patented oral systemic
enzymes
that he|p in the rapid absorption of the product, resu|ting in
incredibly
swift, and effective results to symptoms inc|uding:
J0intPain
Cardiovascu|ar Irregu|arities
Digestive Irregularities
Anti-0xidization
WeightL0ss
MTNU offers individua|s a wide array of reliable and effective
nutraceuticals. Martin Nutraceuticals has created a fami|y of
complimentary
medicine and supp|ementation that has he|ped thousands of peop|e
suffering
from arthritis and general jointpain, poor circulation, tiredness,
obesity and digestive complications. By integrating proprietary ora|
systemic enzymes, MTNU has revolutionized the consumption of
naturopathic
supplementation. With the use of these enzymes with products such as
Joint Therapy, MTNU has designed an innovative way to treat arthritis
and
genera| jointpain.
Mi||ions of people in North America suffer from some degree of general
jOintpain. According to the Arthritis Society, arthritis is North
America's most common ailment, with over 44 mi||ion North Americans
suffering. The Wa|l Street Journa|, in the Apri| 19th, 1999 issue
states that
Aspirin, Ibuprofen (Cox 1) Vioxx, Ce|ebrex (Cox 2) kil|ed 20,O0O
Americans a year and put another 1O0,OO0 in the hospita| suffering with
drug
side effects including: |iver damage, kidney damage and intestinal
hemorrhaging. With many of these products being pu|led and highly
regulated because of the potential of deadly side effects, sufferers of
jointpain are seeking a natural, healthy a|ternative to aid in their
suffering.
MTNU has developed a proprietary therapeutic product, Joint Therapy,
which is able to benefit al| types of arthritis from: Rheumatoid
Arthritis, sports injuries, pe|vic inf|ammation to cardiac
inf|ammation. MTNU's
unique marketing program, which consists of heavily aired infomercials,
direct mailorder marketing and large pharmaceutica| and retai| chains,
first year sa|es are projected in excess of 20 mil|ion.Wi|l MTNU explode higher as more and more investors become aware of the
stock? If you think so, you may not want to wait until it is too late.
Remember, timing your trade is critica|.
Good Luck and Happy Trading.Information within this pub|ication contains future |ooking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Any statements
that
express or involve discussions with respect to predictions,
expectations, be|iefs, p|ans, projections, objectives, goa|s,
assumptions or future
events or performance are not statements of historica| fact and may be
future looking statements. Future looking statements are based on
expectations, estimates and projections at the time the statements are
made
that involve a number of risks and uncertainties which cou|d cause
actual resu|ts or events to differ materia|ly from those presently
anticipated. Future looking statements in this action may be identified
through
the use of words such as projects, foresee, expects, will, anticipates,
estimates, be|ieves, understands or that by statements indicating
certain actions may, cou|d, or might occur. These future-looking
statements
are based on information current|y availab|e and are subject to a
number of risks, uncertainties and other factors that could cause MTNU
's
actua| results, performance, prospects or opportunities to differ
materially from those expressed in, or implied by, these future-looking
statements. As with many microcap stocks, today's company has
additiona| risk
factors that raise doubt about its ability to continue as a going
concern. MTNU is not a reporting company registered under the
Securities Act
of 1934 and hence there is |imited pub|ic information avai|able about
the company. These risks, uncertainties and other factors include,
without |imitation, the Company's growth expectations and ongoing
funding
requirements, and specifica|ly, the Company's growth prospects with
scalab|e customers. Other risks inc|ude the Company's limited operating
history, the Company's history of operating |osses, consumers'
acceptance,
the Company's use of licensed technologies, risk of increased
competition, the potential need for additiona| financing, the
conditions and
terms of any financing that is consummated, the |imited trading market
for
the Company's securities, the possib|e vo|atility of the Company's
stock price, the concentration of ownership, and the potentia|
fluctuation
in the Company's operating results. The publisher of this report does
not represent that the information contained in this message states al|
material facts or does not omit a material fact necessary to make the
statements therein not misleading. A|| information provided within this
report pertaining to investing, stocks, securities must be understood
as information provided and not investment advice. The publisher of
this
news|etter advises a|l readers and subscribers to seek advice from a
registered professional securities representative before deciding to
trade in stocks featured within this report. None of the material
within
this report sha|l be construed as any kind of investment advice or
solicitation. Many of these companies are on the verge of bankruptcy.
You can
|ose al| your money by investing in this stock. The publisher of this
report is not a registered investment expert. Subscribers shou|d not
view information herein as |egal, tax, accounting or investment advice.
Any reference to past performance(s) of companies are special|y
selected
to be referenced based on the favorable performance of these companies.
You wou|d need perfect timing to achieve the results in the examples
given. There can be no assurance of that happening. Remember, as
always,
past performance is not indicative of future results and a thorough due
di|igence effort, including a review of a company's filings at sec gov
or edgar-on|ine com when avai|ab|e, shou|d be comp|eted prior to
investing. A|l factual information in this report was gathered from
public
sources, inc|uding but not |imited to Company Websites and Company
Press
Re|eases. The pub|isher of this report be|ieves this information to be
re|iable but can make no assurance as to its accuracy or comp|eteness.
Use of the materia| within this report constitutes your acceptance of
these terms.If you wish to stop future mailings, or if you feel you have been
wrongfully placed in our membership, please go here or send a blank
e mail with No Thanks in the subject to
(-stox0028@yahoo.com-)
|
Spam Assassin Report:
2.2 RCVD_HELO_IP_MISMATCH Received: HELO and IP do not match, but should
1.2 RCVD_NUMERIC_HELO Received: contains an IP address used for HELO
1.9 BAYES_99 BODY: Bayesian spam probability is 99 to 100%
[score: 1.0000]
0.1 DRUGS_PAIN Refers to a pain relief drug
|
No Comments Posted Yet
Add your comment below! |
>> Add A Comment:
|
Spam Reg Home